At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Ibrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
In Brief
A Phase 2 clinical trial evaluating Ibrutinib and Venetoclax for Refractory Follicular Lymphoma and Relapsed Follicular Lymphoma. Completed, enrolled 24 participants across 3 sites.
Detailed Summary
This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAbbVie, Pharmacyclics LLC., Hackensack Meridian Health
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartMar 2017
Primary CompletionMay 2023
Study CompletionMar 2024
TodayJul 2026
First PostedNov 7, 2016
Enrollment StartMar 1, 2017
Primary CompletionMay 23, 2023
Study CompletionMar 7, 2024
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 9.7 years ago
Interventions
Ibrutinibdrug
Ibrutinib is dispensed as a capsule.
Venetoclaxdrug
Venetoclax is dispensed as a tablet.